Highlights from ESMO 2020 Virtual

touchCONGRESS for touchONCOLOGY

Listen to key highlights from ESMO Virtual 2020. This touchPODCAST is presented by Dr Catherine Kelly. 

We specifically focus on data presented at this congress describing CDK4/6 inhibitors in HR+/HER2- breast cancer and what these data could mean for clinical practice. 

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical educational grant from Eli Lilly. This activity is provided by touchIME.

For further information visit our website: https://touchoncologyime.org/hrher2-breastcanceresmo2020touchcongress/